O-glucogenistein inhibits eosinophil recruitment and nasal allergic symptoms in a murine model of nasal allergy.
- Author:
Hong Ryul JIN
1
;
Bora SOHN
;
Yuan Xi ZHE
;
Young soo KIM
;
Sang Hun JUNG
;
Seung Ho LEE
;
Jae Chun RYU
;
Mi Kyeong KIM
Author Information
1. Department of Otorhinolaryngology, Chungbuk National University, Cheongjoo, Korea.
- Publication Type:Original Article
- Keywords:
Sophoricoside;
eosinophil;
IL-5;
nasal allergic symptoms;
murine allergy model
- MeSH:
Animals;
Antibody Formation;
Cytokines;
Eosinophilia;
Eosinophils*;
Genistein;
Humans;
Hypersensitivity*;
Immunoglobulin E;
Inflammation;
Interleukin-5;
Male;
Mice;
Nasal Mucosa;
Sophora;
Tyrosine
- From:Journal of Asthma, Allergy and Clinical Immunology
2003;23(3):467-473
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Infiltration of eosinophils in the nasal mucosa is a consistent feature of nasal allergic inflammation. Various cytokines, especially interleukin-5(IL-5), were identified to play important roles in the infiltration and activation of eosinophils in nasal mucosa. Our previous study found that among 4 kinds of sophoricosides extracted from Sophora japonica, named sophi, orobol, genistin, and genistein, 3 compounds except genistein known as protein tyrosine kinase(PTK) inhibitor had anti-inflammatory and anti-IL-5 effects, and sophi was the most potent. OBJECTIVE: The goal of this study was to investigate the antagonism of sophi on the nasal eosinophilia in ovalbumin(OA)-sensitized murine nasal allergy model. METHODS: Male BALB/c mice sensitized intraperitoneally and then topically with OA were treated with sophi(10 or 30mg/kg) or anti-mouse IL-5 monoclonal antibody(anti-IL-5 mAb, 1mg/Kg) intravenously 1 hour before challenge. The effect of sophi on the infiltration of eosinophils into the nasal mucosa, peripheral blood eosinophilia, nasal symptom, and OA-specific IgE antibody production were evaluated. Results: Administration of sophi(10, 30mg/kg) significantly inhibited the nasal eosinophil infiltration and nasal symptom compared to that of anti-IL-5 mAb. But eosinophil count inthe peripheral blood and the titer of OA-specific IgE were not affected by sophi. CONCLUSION: Sophi inhibited not only the tissue eosinophilia but also the acute nasal allergic symptom. These findings suggest that sophi has anti-eosinophilic cytokine activity and also plays blockade of early allergic reaction. Taken together, sophi may be a candidate for new anti-allergic medicine.
